Edgewise to Sell Muscle Dystrophy Unit to Servier for Up to $2.65 Billion

• Servier gains global rights to sevasemten, which showed muscle function benefits in Becker muscular dystrophy patients and favorable safety profile in trials for both Becker and Duchenne muscular dystrophy
• Becker muscular dystrophy currently has no approved treatments, while the more severe Duchenne form has several drugs including Sarepta's gene therapy Elevidys
• The transaction is expected to close in Q3 2025 and aligns with Servier's 2030 ambition in neurology, while Edgewise refocuses on EDG-7500 for hypertrophic cardiomyopathy with mid-stage trial data expected in Q2

Edgewise Therapeutics Sells Muscular Dystrophy Unit to Servier for Up to $2.65 Billion

Edgewise Therapeutics announced on June 1 it will divest its experimental muscular dystrophy drug business to French pharmaceutical company Servier in a deal valued at up to $2.65 billion. The transaction includes $1.55 billion in upfront cash, with an additional $1.1 billion available through milestone payments.

Deal Structure:

Servier will acquire global rights to sevasemten, Edgewise's lead muscular dystrophy candidate, along with associated intellectual property, clinical data, and program staff. The transaction is expected to close in Q3.

Drug Profile:

Sevasemten is being developed for Becker and Duchenne muscular dystrophy, both genetic disorders causing progressive muscle weakness. Clinical trials have demonstrated muscle function improvements in Becker patients and reduced muscle damage markers with a favorable safety profile. Notably, while Duchenne has several approved treatments including Sarepta Therapeutics' gene therapy Elevidys, Becker currently has no approved therapies, representing a significant unmet medical need.

Strategic Rationale:

Servier President Olivier Laureau stated the acquisition advances the company's "Servier 2030 ambition in neurology." For Edgewise, the sale strengthens its balance sheet and allows focus on its lead pipeline candidate EDG-7500, currently in mid-stage trials for hypertrophic cardiomyopathy—a condition causing heart muscle thickening that impairs blood pumping. Twelve-week data from EDG-7500's Phase 2 trial is expected in Q2.

Market Implications:

The deal highlights continued consolidation in the rare disease space and validates the commercial potential of muscular dystrophy treatments, particularly in underserved Becker patients.